Vinod N, Hwang D, Fussell S, Owens T, Tofade O, Benefield T
Bioeng Transl Med. 2024; 9(5):e10681.
PMID: 39553439
PMC: 11561794.
DOI: 10.1002/btm2.10681.
Du J, Wu S, Liu J, Guo B, Li J, Li W
Cytojournal. 2024; 21:31.
PMID: 39411170
PMC: 11474753.
DOI: 10.25259/Cytojournal_15_2024.
Steenbrugge J, Pauwelyn G, Demeyere K, Devriendt N, de Rooster H, Sanders N
Front Immunol. 2023; 14:1252374.
PMID: 37928528
PMC: 10623058.
DOI: 10.3389/fimmu.2023.1252374.
Wu C, Wang M, Sun J, Jia Y, Zhu X, Liu G
Theranostics. 2023; 13(15):5322-5347.
PMID: 37908727
PMC: 10614680.
DOI: 10.7150/thno.87356.
Zhang J, Zhang Z, Huang Z, Li M, Yang F, Wu Z
Acta Pharm Sin B. 2023; 13(7):2990-3007.
PMID: 37521871
PMC: 10372922.
DOI: 10.1016/j.apsb.2023.05.006.
Combination of Polymeric Micelle Formulation of TGFβ Receptor Inhibitors and Paclitaxel Produce Consistent Response Across Different Mouse Models of TNBC.
Vinod N, Hwang D, Fussell S, Owens T, Tofade O, Copling S
bioRxiv. 2023; .
PMID: 37398150
PMC: 10312717.
DOI: 10.1101/2023.06.14.544381.
Tumor-Targeting Extracellular Vesicles Loaded with siS100A4 for Suppressing Postoperative Breast Cancer Metastasis.
Pan R, He T, Zhang K, Zhu L, Lin J, Chen P
Cell Mol Bioeng. 2023; 16(2):117-125.
PMID: 37096069
PMC: 10121989.
DOI: 10.1007/s12195-022-00757-5.
NADPH Selective Depletion Nanomedicine-Mediated Radio-Immunometabolism Regulation for Strengthening Anti-PDL1 Therapy against TNBC.
Wang Y, Gao D, Jin L, Ren X, Ouyang Y, Zhou Y
Adv Sci (Weinh). 2022; 10(3):e2203788.
PMID: 36403210
PMC: 9875612.
DOI: 10.1002/advs.202203788.
In-Silico Drug Toxicity and Interaction Prediction for Plant Complexes Based on Virtual Screening and Text Mining.
Zhang F, Ganesan K, Li Y, Chen J
Int J Mol Sci. 2022; 23(17).
PMID: 36077464
PMC: 9456415.
DOI: 10.3390/ijms231710056.
Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities.
Ribeiro R, Carvalho M, Goncalves J, Moreira J
Front Mol Biosci. 2022; 9:903065.
PMID: 36060249
PMC: 9437219.
DOI: 10.3389/fmolb.2022.903065.
Breast cancer cell-derived extracellular vesicles promote CD8 T cell exhaustion via TGF-β type II receptor signaling.
Xie F, Zhou X, Su P, Li H, Tu Y, Du J
Nat Commun. 2022; 13(1):4461.
PMID: 35915084
PMC: 9343611.
DOI: 10.1038/s41467-022-31250-2.
Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment.
Acurcio R, Pozzi S, Carreira B, Pojo M, Gomez-Cebrian N, Casimiro S
J Immunother Cancer. 2022; 10(7).
PMID: 35863821
PMC: 9310269.
DOI: 10.1136/jitc-2022-004695.
Insights into breast cancer phenotying through molecular omics approaches and therapy response.
Belizario J, Loggulo A
Cancer Drug Resist. 2022; 2(3):527-538.
PMID: 35582587
PMC: 8992536.
DOI: 10.20517/cdr.2018.009.
Light-controllable charge-reversal nanoparticles with polyinosinic-polycytidylic acid for enhancing immunotherapy of triple negative breast cancer.
Fang L, Zhao Z, Wang J, Xiao P, Sun X, Ding Y
Acta Pharm Sin B. 2022; 12(1):353-363.
PMID: 35127391
PMC: 8800000.
DOI: 10.1016/j.apsb.2021.06.006.
Immunotherapy toxicity: identification and management.
Gumusay O, Callan J, Rugo H
Breast Cancer Res Treat. 2022; 192(1):1-17.
PMID: 35015209
PMC: 8841316.
DOI: 10.1007/s10549-021-06480-5.
An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity.
Zhou Z, Van der Jeught K, Fang Y, Yu T, Li Y, Ao Z
Nat Biomed Eng. 2021; 5(11):1320-1335.
PMID: 34725507
PMC: 8647932.
DOI: 10.1038/s41551-021-00805-x.
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).
Adams S, Othus M, Patel S, Miller K, Chugh R, Schuetze S
Clin Cancer Res. 2021; 28(2):271-278.
PMID: 34716198
PMC: 8776596.
DOI: 10.1158/1078-0432.CCR-21-2182.
Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy.
Zhang W, Kong X, Ai B, Wang Z, Wang X, Wang N
Front Oncol. 2021; 11:582664.
PMID: 34631507
PMC: 8495193.
DOI: 10.3389/fonc.2021.582664.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.
Emens L, Adams S, Cimino-Mathews A, Disis M, Gatti-Mays M, Ho A
J Immunother Cancer. 2021; 9(8).
PMID: 34389617
PMC: 8365813.
DOI: 10.1136/jitc-2021-002597.
A novel role for an old target: CD45 for breast cancer immunotherapy.
Raiter A, Zlotnik O, Lipovetsky J, Mugami S, Dar S, Lubin I
Oncoimmunology. 2021; 10(1):1929725.
PMID: 34104545
PMC: 8158046.
DOI: 10.1080/2162402X.2021.1929725.
